Evidence map›Paper›PMID 40751268›Full record

ReviewMolecular brain2025

Neurodegeneration in Parkinson's disease: are we looking at the right spot?

Gabriel S Rocha, Marco Aurelio M Freire, Daniel Falcao, Tiago F Outeiro, Rafael R Lima, Jose Ronaldo Santos

Abstract readReview
In one paragraph

Review in Molecular brain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabriel S RochaDepartment of Physiology, Federal University of Sergipe, Aracaju, 49107-230, Brazil.
Marco Aurelio M FreireLaboratory of Behavioral and Evolutionary Neurobiology, Department of Biosciences, Federal University of Sergipe, Itabaiana, SE, 49500-000, Brazil.
Daniel FalcaoVCU Health Systems, Virginia Commonwealth University, Richmond, 23284, USA.
Tiago F OuteiroDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
Rafael R LimaInstitute of Biological Sciences, Federal University of Pará, Belém, 66075-110, Brazil.
Jose Ronaldo SantosLaboratory of Behavioral and Evolutionary Neurobiology, Department of Biosciences, Federal University of Sergipe, Itabaiana, SE, 49500-000, Brazil. joseronaldosantos@gmail.com.

Funding

Coordination of Superior Level Staff Improvement (CAPES) Finance Code 001National Council for Scientific and Technological Development (CNPq) 312275/2021-8
6 · The paper itself

Abstract

Parkinson's disease (PD) is recognized as the fastest-growing neurodegenerative disorder, impacting millions of individuals worldwide. It is primarily characterized by cardinal motor symptoms, including bradykinesia (slowness of movement), tremor, rigidity, and postural instability, which significantly impair the quality of life of those affected. Traditionally, the prevailing hypothesis has attributed these motor symptoms to the degeneration and subsequent loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Currently, emerging research suggests that this neuron-centric view may be overly simplistic and not entirely accurate. In light of this, growing attention has turned to the role of axons within the nigrostriatal pathway-an extensive network connecting the substantia nigra to the striatum, essential for both dopamine transmission and the overall functioning of the motor control by the brain. By directing a focus toward this aspect, in this nano review article we examine why nigrostriatal axons deserve increased attention and should be considered a pivotal target for further therapeutic strategies in PD.

Indexed as

Nerve DegenerationParkinson DiseaseAnimalsAxonsDopaminergic NeuronsHumansSubstantia NigraAxonsCell deathDopamineNeural transmissionParkinsonism

Identifiers

PMID40751268
PMCPMC12315329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.